PHARMACEUTICAL ONLINE EDITORIAL ADVISORY BOARD

We’re building the inaugural Pharmaceutical Online Editorial Advisory Board. If you’re passionate about sharing your pharmaceutical manufacturing knowledge, we invite you to connect with Chief Editor Katie Anderson to explore advisory board opportunities.

Kerri Finnegan is a highly accomplished executive with more than 30 years of expertise in the pharmaceutical and environmental sectors. She currently serves as Vice President, Human Pharma US Supply & Quality for Boehringer Ingelheim Pharmaceuticals, Inc., based in Columbus, Ohio. Since joining Boehringer Ingelheim in 1993, Kerri has taken on numerous leadership roles within the organization. Her distinguished career includes positions such as Head of Human Pharma US Supply, Executive Director of 3rd Party North America & Technical Services, Executive Director of Compliance Services, and Director of Learning & Development. In addition, Kerri broadened her global perspective through an international assignment as Manager of Corporate Quality Assurance in Ingelheim, Germany. Throughout her tenure at Boehringer Ingelheim, Finnegan has been acknowledged for her ability to drive operational excellence, ensure regulatory compliance, and lead cross-functional teams in complex environments. Her impactful leadership continues to contribute to the success of the company.
   
Dennis Hall is Vice President of Advanced Manufacturing Technologies for US Pharmacopeia, where he leads a team charged with identifying new manufacturing or other enabling technologies and deploying services and solutions to support adoption of these advanced manufacturing technologies. Through these solutions, USP can help detect where complications or problems exist, deploy their best science to solve these problems, and then scale those solutions through USP’s broad reach to industry, regulators, and academia. Hall has been a key leader at USP since 2001 in a variety of areas including strategy, marketing, and leading USP’s global growth initiative focused on Asia, Europe, and Latin America. He holds an MBA in strategic management and marketing from the University of Maryland, a master’s degree in education from the College of William and Mary, and a bachelor’s degree in physics from Clarion University of Pennsylvania. 
   
Bernard Kiernan, Ph.D., is a veteran biopharmaceutical executive with over two decades of specialized expertise in pharmaceutics, product development, and Chemistry, Manufacturing, and Controls (CMC). He currently serves as the Executive Director of Pharmaceutical Science, CMC and Supply Chain for Madrigal Pharmaceuticals. Prior to Madrigal, he served as Vice President and Head of CMC for AMO Pharma Ltd. Throughout his career, which includes pivotal leadership tenures as Product Development Director at Shire and Associate Director at Biovail, Kiernan has successfully guided complex small molecule and advanced biologic therapies from early clinical formulation through global regulatory approval and commercial scale-up. He holds a PhD in Pharmaceutics from Saint Joseph's University (Philadelphia College of Pharmacy).
   
Ryan Littich, Ph.D., is Chief Technical Officer at the Medicines for All Institute (M4ALL) of Virginia Commonwealth University, where he leads Platform Innovation, API Development Services, and Manufacturing Science & Technology organizations. Before joining M4ALL, Littich was Head of Advanced Chemistry Technologies, Global R&D at Lonza, where he built and led technology innovation programs, portfolios, and organizations pursuing reductions in drug manufacturing costs, production timelines, and environmental impact. Littich holds a Ph.D. in Organic Chemistry from the University of Texas at Austin and an Executive Certificate in Strategy & Innovation from MIT’s Sloan School of Management.
   
Piyush Modi, BPharm, is a director of regulatory affairs at Amneal Pharmaceuticals, USA. He has over 20 years of experience in pharmaceutical development, specializing in chemistry, manufacturing, and controls (CMC) regulatory strategy. He has extensive expertise in FDA submissions, lifecycle management, and resolving complex regulatory challenges across multiple therapeutic areas. His work focuses on advancing regulatory science through data-driven and innovative approaches to improve submission quality, reduce regulatory risk, and enhance approval outcomes. He has contributed to multiple first-cycle approvals and led initiatives to improve inspection readiness, data integrity, and compliance across manufacturing and regulatory functions. Modi is an active contributor to the regulatory and pharmaceutical science community through peer-reviewed publications, conference participation, and peer review activities.
   
Leo Costa Siqueira is the Vice President of API Manufacturing in the US and Site Head for the API Site of Novo Nordisk in Clayton, North Carolina. He leads API Manufacturing in the U.S. for Novo Nordisk, including API manufacturing operations in North Carolina, New Hampshire, and Indiana. Leo oversees 1,000+ employees across three sites, including scaling up with his team at the API facility in Clayton that supplied all of the oral semaglutide for the launch of Wegovy pill. His facility also now supplies the oral semaglutide for the Ozempic pill. A 22-year Novo Nordisk veteran with experience across Brazil, Denmark, and the U.S., Leonardo was honored with Novo Nordisk's Manager of the Year award in 2025. Siqueira holds a Bachelor of Pharmacy and graduate degrees in both Biochemistry and Pharmacology from leading Brazilian universities, a Clinical Analysis Certification, and an Executive Certification from Harvard Business School.
   

Veena Warikoo, Ph.D., currently serves as the Vice President of Global Technical Operations within Biologics Operations at AstraZeneca. She leads a global team of scientists and engineers who are innovating to enable sustainable supply of medicines to their patients. Prior to joining AstraZeneca, she worked for 25 years in biopharmaceutical industry, written multiple significant publications, innovated on leading edge manufacturing technologies and led implementation of those technologies to benefit the patient access to critical medicines.  Most recently, she was the 2022 award winner for “Integrated Continuous Biomanufacturing” by ECI and “2024 Reuters trailblazing women in supply chain,”
   

Stephanie Wimberly, Ph.D. is a senior pharmaceutical manufacturing executive with over 19 years of expertise in FDA-regulated biopharmaceutical and biotechnology environments. She is currently a manufacturing consultant at APTTMHY. She is a proven leader in advancing quality practices within GMP settings, specializing in quality assurance, regulatory compliance, and operational excellence. Her expertise includes standardizing and optimizing manufacturing processes, leading complex root cause analysis investigations, and managing the entire quality event lifecycle. She is a certified Lean Six Sigma Yellow Belt professional focused on executing strategic company goals through robust process improvement and cross-functional leadership.